Additional chemokines, including the monocyte chemoattractant protein-1 (MCP-1/CCL2) and macrophage inflammatory protein 1a (MIP-1a/CCL3), have been proposed as potential immunotherapeutic agents for leishmaniasis, although current studies have only focused on their use in the treatment of VL [107]. The gene discussed is CCL2; the disease is leishmaniasis.